Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 12Diarrhea 5Rectal Neoplasms 3Sarcoma, Alveolar Soft Part 2Ovarian Neoplasms 2Colorectal Neoplasms 2Vulvar Neoplasms 1Vulvar Diseases 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Urogenital Neoplasms 1Triple Negative Breast Neoplasms 1Short Bowel Syndrome 1Recurrence 1Papillomavirus Infections 1Neoplasms 1Melanoma 1Lymphoma 1Lung Neoplasms 1Low Anterior Resection Syndrome 1Gliosarcoma 1Glioblastoma 1Exanthema 1Esophageal Squamous Cell Carcinoma 1Endometrial Neoplasms 1Colorectal Cancer Metastatic 1Colonic Neoplasms 1Colitis, Ulcerative 1Colitis 1

Interventions

Cyclophosphamide 155Dexamethasone 141Rituximab 85fludarabine 80Lenalidomide 72Cytarabine 70Bortezomib 65fludarabine phosphate 63Gemcitabine 62venetoclax 55pomalidomide 53Etoposide 53pembrolizumab 52Paclitaxel 48Cisplatin 48Carboplatin 48Peripheral Blood Stem Cell Transplantation 47Filgrastim 40Radiotherapy 39Busulfan 37Calcium Dobesilate 36Methotrexate 34Melphalan 34Bevacizumab 33carfilzomib 32Cyclosporine 32Azacitidine 32Mycophenolic Acid 30Vincristine 29Bendamustine Hydrochloride 29

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrence × Loperamide × Clear all
NCT06865677 2026-01-21

Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
2 enrolled 7 charts

Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡